Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

Abstract

We did not find a statistically significant relationship between mutations of k-ras, b-raf, or p53 and the increase in median survival associated with the addition of bevacizumab to IFL in metastatic colorectal cancer.